Author

E Loftus

Observed name: E V Loftus

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5123479396

DOP055 Efficacy and Safety Up to 3 Years of Risankizumab Maintenance Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Results from Phase 3 COMMAND Open-Label Extension Study

2026 · R Atreya, E Louis, et al. · Journal of Crohn s and Colitis · 1

OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study

2026 · E Louis, V Jairath, et al. · Journal of Crohn s and Colitis · 1

P0774 Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

2026 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis

P0762 Defining Quality Pouch Surgery – A Critical Step Towards Centralization? International Consensus on Key Performance Indicators in Pouch Surgery (KPIPS) Study

2026 · S Holubar, M Soop, et al. · Journal of Crohn s and Colitis

DOP085 Baseline predictors and clinical outcomes of risankizumab dose optimization: a real-world multicenter retrospective study

2026 · A Johnson, P R Ramesh, et al. · Journal of Crohn s and Colitis

P0749 Association of endoscopic outcomes with long-term clinical improvements in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study

2026 · E Loftus, E Louis, et al. · Journal of Crohn s and Colitis

Early and sustained efficacy of delayed-release oral Mesalamine in moderately active ulcerative Colitis patients: Combined results from the ASCEND I, II, & III trials

2008 · G Lichtenstein, D Ramsey, et al. · Inflammatory Bowel Diseases

Works count: 7

Citation count: 2

H-index: 1

I10-index: